SCHNEIDERMAN JACOB has a total of 19 patent applications. It decreased the IP activity by 50.0%. Its first patent ever was published in 2005. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets medical technology, pharmaceuticals and optics are FED GOSUDARSTVENNOE BYUDZHETNOE UCHREZHDENIE NATSIONALNYJ MEDITSINSKIJ ISSLEDOVATELSKIJ RADIOLOGICHE, BIOLIFE LLC and SHANGHAI NINTH PEOPLES HOSPITAL AFFILIATED TO SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 8 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | Canada | 3 | |
#4 | EPO (European Patent Office) | 2 | |
#5 | Israel | 2 |
# | Industry | |
---|---|---|
#1 | Medical technology | |
#2 | Pharmaceuticals | |
#3 | Optics | |
#4 | Measurement | |
#5 | Macromolecular chemistry and polymers | |
#6 | Micro-structure and nano-technology |
# | Technology | |
---|---|---|
#1 | Diagnosis and surgery | |
#2 | Object sterilising | |
#3 | Medical preparations | |
#4 | Implantable devices | |
#5 | Syringes | |
#6 | Analysing materials | |
#7 | Nanostructure applications | |
#8 | Macromolecular compounds compositions | |
#9 | Electrotherapy | |
#10 | Optical systems |
# | Name | Total Patents |
---|---|---|
#1 | Schneiderman Jacob | 19 |
#2 | Cohen Moshik | 8 |
#3 | Moshik Cohen | 1 |
Publication | Filing date | Title |
---|---|---|
US2019060531A1 | Treatment of ischemia and reperfusion using leptin antagonist | |
US2020375719A1 | Method and device for localized intravascular therapy | |
US2019022286A1 | Drug eluting stent | |
WO2017141246A1 | Drug eluting stent | |
EP3374758A1 | Systems and methods for identifying and treating biological materials | |
CA2977607A1 | Methods and compositions relating to leptin antagonists | |
US2016250294A1 | Composition-of-matter and method for treating cardiovascular disorders | |
US2007088379A1 | Minimally invasive a AAPT extirpation |